403 reports of this reaction
1.8% of all EPOPROSTENOL SODIUM reports
#11 most reported adverse reaction
FATIGUE is the #11 most commonly reported adverse reaction for EPOPROSTENOL SODIUM, manufactured by GlaxoSmithKline LLC. There are 403 FDA adverse event reports linking EPOPROSTENOL SODIUM to FATIGUE. This represents approximately 1.8% of all 22,890 adverse event reports for this drug.
Patients taking EPOPROSTENOL SODIUM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for EPOPROSTENOL SODIUM, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for EPOPROSTENOL SODIUM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 403 FDA reports for EPOPROSTENOL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.8% of all adverse event reports for EPOPROSTENOL SODIUM, making it a notable side effect.
If you experience fatigue while taking EPOPROSTENOL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.